In 2H, 2018, TAXIS will raise $2.5M in convertible preferred debt funding to further expand and characterize the Efflux Pump Inhibitor platform, advance the MreB discovery program and complete FIH study of our lead gram-positive, QIDP-designated drug candidate, TXA709. We have raised$13.5M since inception from private investors including angels and prominent family offices.

TAXIS is engaged with multiple pharmaceutical companies with the intention to license or sell some or all of its technology platform in 2019/20.